Research Advances in Depression and Antidepressant Drugs
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 4
Special Issue Editors
Interests: depression; anxiety; epilepsy; preclinical studies; neuroscence; phamaceutical care; neuropharmacology; experimental pharmacology; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Interests: depression; anxiety; epilepsy; preclinical studies; neuroscence; phamaceutical care; neuropharmacology; experimental pharmacology; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
According to disturbing statistics, more than 320 million people worldwide suffer from depressive disorders, and this number is quickly increasing. The disease has many overlapping causes, including biological, psychological, and social factors. Despite enormous progress in the field of psychiatry, the management of depression is difficult. It has been estimated that ca. 40% of patients with depressive disorders do not respond to antidepressant drugs, about 60% are not successful in achieving complete remission, and even up to 85% of depressive people present with relapse of the disease. Currently, available antidepressants have a delayed onset of action and can induce frustrating side effects, which may have a negative impact on the patient’s approach to the prescribed therapy. Thus, the medical world is searching for novel, more effective strategies for the management of depressive disorders.
In our Special Issue, we would like to bring together experts working in the field of psychiatry, neuroscience, and neuropharmacology and invite them to present their opinions, suggestions, and findings related to the new, experimental, and promising treatment options for depressive disorders. We encourage the submission of original research articles as well as reviews on experimental models and biomarkers of depression, biological pathways and molecular mechanisms related to the pathophysiology of this disease, as well as on novel/promising targets of antidepressant action. Due to the scope of IJMS, pure reports from clinical trials will not be accepted, but clinical submissions with biomolecular experiments are welcomed.
Dr. Anna D. Serefko
Dr. Aleksandra Szopa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- depression
- antidepressant drugs
- preclinical studies
- biomolecular expetiments
- drug development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
